Par Pharmaceutical Inc, an operating company of Ireland-based Endo International plc (NASDAQ: ENDP) announced on Tuesday that it has started shipping the first generic version of Merz's CUVPOSA (glycopyrrolate) 1mg/5mL oral solution in the United States.

This move is subsequent to the final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application. According to IQVIA, CUVPOSA sales were approximately USD27m for the 12 months ended 31 October 2021.

Jon Holden, senior vice president and general manager, Generics at Endo, said, 'We're proud to provide families with a generic option of this important medication. Glycopyrrolate oral solution joins our extensive portfolio of high-quality, lower-cost generic products--and our reputation for dependable quality is an especially essential factor when treating children.'

CUVPOSA is a registered trademark of Merz Pharmaceuticals LLC.